Search Submit Your Manuscript

Become A Member

  1. Home
  2. Novemeber 2019
  3. 8. Efficacy of Spectinomycin versus Ceftriaxone in the Treatment of Gonorrhea
Article Image

8. Efficacy of Spectinomycin versus Ceftriaxone in the Treatment of Gonorrhea

Tayaba Basharat1, Shandana Altaf2, Muhammad Iftikhar Adil3 and Waheed Iqbal2


Objective: The aim of this study was to compare the efficacy of spectinomycin verses ceftriaxone in the treatment of gonococcal infection.

Study Design: Observational Study

Place and Duration of Study: This study was conducted at the Nowshera Medical College, Nowshera Pakistan during the period of January 2017 to December 2018.

Materials and Methods: Purposive sampling technique was used to enroll the patients. Two hundred patients were enrolled for the study. The patients were randomly divided into two groups of 100 patients each. Group A was given injection spectinomycin 2gm intramuscularly and Group B was given Injection Ceftriaxone 500mg intramuscularly in single dosage. All the patients were reexamined after 5 days and their clinical and laboratory findings were recorded and analyzed.

Results: The patients in Group A (n=100) who were given spectinomycin Showed 94% full response, 4% partial response and 2% no response, while the patients in Group B (n=100) who were given ceftriaxone showed 90% full response, 4% partial response and 6% showed no response at all. Furthermore, increasing age does not play any statistically significant role in etiology of gonorrhea infection.

Conclusion: There is no statistically significant difference between cure rates of spectinomycin and ceftriaxone. However, due to pain at injection site, less effective in pharyngeal gonorrhea, contraindication in pregnancy and breast feeding, the spectinomycin may be reserved only for ceftriaxone resistant cases.

Key Words: Neisseria Gonorrhea, Spectinomycin, Ceftriaxone

Citation of article: Basharat T, Altaf S, Adil MI, Iqbal W. Efficacy of Spectinomycin Versus Ceftriaxone in the Treatment of Gonorrhea. Med Forum 2019;30(11):27-30.